gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4494 131410-48-5

Description:

MoleculeDescription

Synonyms:

  • omniscan
  • gadodiamide
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
  • Molecular weight: 573.66
  • Formula: C16H26GdN5O8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.79 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.46 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 8, 1993 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2221.55 55.36 349 2613 4116 56284989
Skin hypertrophy 407.91 55.36 79 2883 3131 56285974
Skin induration 406.54 55.36 78 2884 2940 56286165
Skin tightness 309.29 55.36 65 2897 3890 56285215
Fibrosis 198.22 55.36 45 2917 3846 56285259
Skin fibrosis 197.87 55.36 35 2927 829 56288276
Skin hyperpigmentation 153.51 55.36 39 2923 5358 56283747
Joint range of motion decreased 136.55 55.36 51 2911 25314 56263791
Joint contracture 110.37 55.36 24 2938 1678 56287427
Scar 105.14 55.36 35 2927 12398 56276707
Emotional distress 94.70 55.36 41 2921 29722 56259383
Skin discolouration 92.20 55.36 42 2920 34314 56254791
Anhedonia 80.20 55.36 27 2935 9887 56279218
Peau d'orange 76.28 55.36 12 2950 134 56288971
Joint stiffness 72.65 55.36 36 2926 35389 56253716
Oedema peripheral 70.99 55.36 64 2898 171190 56117915
Erythema 70.05 55.36 61 2901 155878 56133227
Mobility decreased 68.63 55.36 50 2912 98941 56190164
Skin plaque 64.24 55.36 21 2941 7017 56282088
Muscle contracture 61.21 55.36 14 2948 1230 56287875
Extremity contracture 60.83 55.36 14 2948 1265 56287840
Deformity 60.19 55.36 22 2940 10233 56278872
Pain 59.37 55.36 116 2846 663068 55626037
Magnetic resonance imaging head abnormal 55.87 55.36 14 2948 1812 56287293

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2296.10 53.98 386 2782 3569 31690607
Skin hypertrophy 378.09 53.98 79 3089 2386 31691790
Skin tightness 357.19 53.98 73 3095 1971 31692205
Skin induration 356.55 53.98 73 3095 1989 31692187
Joint range of motion decreased 238.71 53.98 66 3102 6595 31687581
Joint contracture 237.51 53.98 51 3117 1752 31692424
Skin fibrosis 217.60 53.98 43 3125 970 31693206
Fibrosis 180.49 53.98 43 3125 2366 31691810
Scar 167.19 53.98 48 3120 5482 31688694
Extremity contracture 132.97 53.98 27 3141 700 31693476
Deformity 128.61 53.98 30 3138 1503 31692673
Emotional distress 125.80 53.98 49 3119 14307 31679869
Mobility decreased 122.16 53.98 58 3110 27411 31666765
Joint stiffness 112.45 53.98 41 3127 9980 31684196
Anhedonia 104.60 53.98 36 3132 7406 31686770
Pain 85.87 53.98 99 3069 186660 31507516
Oedema peripheral 84.66 53.98 77 3091 109762 31584414
Injury 82.64 53.98 40 3128 19669 31674507
Skin disorder 70.47 53.98 31 3137 12250 31681926
Skin discolouration 68.05 53.98 33 3135 16274 31677902
Skin hyperpigmentation 64.56 53.98 20 3148 2951 31691225
Musculoskeletal stiffness 64.48 53.98 44 3124 41281 31652895

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 3114.19 52.88 503 4194 5549 70918198
Skin hypertrophy 615.65 52.88 123 4574 4529 70919218
Skin induration 589.03 52.88 117 4580 4178 70919569
Skin tightness 528.30 52.88 110 4587 4980 70918767
Skin fibrosis 319.68 52.88 59 4638 1406 70922341
Joint range of motion decreased 276.52 52.88 92 4605 25934 70897813
Joint contracture 268.62 52.88 55 4642 2277 70921470
Fibrosis 243.54 52.88 58 4639 4836 70918911
Scar 195.78 52.88 61 4636 13920 70909827
Biopsy brain abnormal 174.34 52.88 21 4676 8 70923739
Skin hyperpigmentation 172.72 52.88 47 4650 6668 70917079
Joint stiffness 140.88 52.88 61 4636 35115 70888632
Oedema peripheral 136.68 52.88 116 4581 227975 70695772
Emotional distress 131.21 52.88 59 4638 37129 70886618
Skin discolouration 131.00 52.88 59 4638 37266 70886481
Mobility decreased 124.36 52.88 80 4617 102919 70820828
Anhedonia 122.47 52.88 43 4654 14170 70909577
Extremity contracture 116.30 52.88 26 4671 1634 70922113
Deformity 115.25 52.88 36 4661 8261 70915486
Peau d'orange 103.86 52.88 18 4679 295 70923452
Skin disorder 100.21 52.88 46 4651 30311 70893436
Pain 91.76 52.88 155 4542 628661 70295086
Erythema 86.98 52.88 85 4612 199478 70724269
Muscle contracture 83.64 52.88 21 4676 2173 70921574
Skin plaque 81.97 52.88 29 4668 9754 70913993
Injury 72.10 52.88 48 4649 65197 70858550
Musculoskeletal stiffness 68.19 52.88 65 4632 147695 70776052
Magnetic resonance imaging head abnormal 66.66 52.88 18 4679 2474 70921273
Pruritus 63.67 52.88 95 4602 345465 70578282
Muscle tightness 62.56 52.88 25 4672 11737 70912010
Skin exfoliation 61.63 52.88 39 4658 48587 70875160
Anxiety 59.49 52.88 73 4624 220257 70703490
Pain of skin 58.73 52.88 23 4674 10243 70913504
Muscular weakness 58.46 52.88 58 4639 138278 70785469
Magnetic resonance imaging abnormal 57.78 52.88 17 4680 3183 70920564
Gait disturbance 57.68 52.88 66 4631 185040 70738707
Dry skin 54.30 52.88 38 4659 55893 70867854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08CA03 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Magnetic resonance imaging indication 113091000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04284 KEGG_DRUG
4020689 VUID
N0000148302 NUI
4020689 VANDF
CHEBI:31642 CHEBI
CHEMBL1200346 ChEMBL_ID
C064925 MESH_SUPPLEMENTAL_RECORD_UI
6636 INN_ID
DB00225 DRUGBANK_ID
84F6U3J2R6 UNII
41144 RXNORM
10205 MMSL
4771 MMSL
d04083 MMSL
004259 NDDF
354088005 SNOMEDCT_US
396067007 SNOMEDCT_US
C0082646 UMLSCUI
153921 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0691 INJECTION 287 mg INTRAVENOUS NDA 28 sections